Last week, GenomeWeb's readers were most interested in Illumina plans to launch a new chip for its NovaSeq instrument and upgrades to its iSeq sequencer in Q1.
CellMax is developing and applying its CTC platform for early detection of colorectal cancer and more long term for breast and prostate cancer.
At the Plant and Animal Genome conference, Daniel Promislow provided details on the longitudinal, open science effort, which is preparing to study up to 10,000 pet dogs.
The partnership with Finnish medical data sciences services vendor MedEngine will help BC Platforms offer end-to-end services for pharma and health-tech companies.
The VISTA T cell-inhibiting protein found on macrophage immune cells may contribute to poor pancreatic ductal adenocarcinoma outcomes, new research finds.
The issue, discovered in late October, affected TMB reporting for up to 800 FoundationOne CDx tests during a short period of time and was quickly resolved.
Novogene's Chinese clinical lab will offer LifeMap's recently updated TGex next-generation sequencing data analysis and interpretation platform.
Meridian CEO Jack Kenny said the firm needs to develop a new MDx platform, while Genapsys resurfaced with an update on its portable sequencing platform.
The company plans to use the funding to further develop its Xdrop technology, which allows users to partition millions of single molecules in droplets.
The protease-activated Cas9 enzymes could reduce off-target effects and could be used to sense pathogens and trigger an immune response.
The company believes that helping to funnel patients to the trial will help support its own goals to gather genomic information on targeted cancer therapy efficacy.
In an epigenome-wide association study, researchers uncovered more than 1,000 sex-related differentially methylated positions among chronic lymphocytic leukemia patients.
Lineagen hopes to use PWNHealth's consumer-oriented model to expand access to its testing services for developmental delay and autism spectrum disorder.
Through the JV and strategic partnership, the companies aim to provide precision diagnostic products and services to Hong Kong, Macau, South Korea, and Southeast Asia.
CEO Brad Gray told investors at the JP Morgan Healthcare Conference that he believes the firm's GeoMx has advantages over competitors in the new market.
Among the updates provided at the conference on Wednesday, Luminex discussed development and plans for the Verigene II system, and GenMark touted its ePlex test portfolio.
Gene expression data revealed two groups of human papillomavirus (HPV)-positive oropharyngeal squamous cell carcinomas corresponding to distinct survival outcomes.
Researchers from the PROREPAIR-B study reported that men with germline BRCA2 mutations and prostate cancer had shorter cause-specific survival.
In a small study, melanoma patients with BRAF V600K mutations responded better to immunotherapy while those with V600E mutations had a better response to targeted therapy.
The firm plans to offer more than 13 million shares of its common stock at $.225 per share. The offering will close on or about Jan. 14.
The company plans to focus on increasing its NIPT reimbursement as well as on pharmaceutical deals for its oncology test and launching a kidney transplantation test.
Arbor Biosciences' portfolio includes custom DNA microarrays and oligonucleotide libraries, as well as a line of targeted sequencing panels.
An analysis of UK Biobank data finds hemochromatosis to be more prevalent than thought, according to the BBC.
An analysis finds that female biomedical researchers receive fewer prizes than male ones, and when they do win prizes, they are less prestigious.
In Nature this week: improved genomic analysis using a graph genome reference, tumor mutational burden could predict clinical response to immune checkpoint inhibitors, and more.
Federal researchers tell the Los Angeles Times that the shutdown is causing missed research opportunities as they try to keep their experiments going.